New York Prescription Drug Formulary Reform Implementation

Chartwell Law
Contact

New York’s 2017-2018 Executive Budget, enacted effective April 10, 2017, included significant reforms to the Workers’ Compensation Law (WCL). This update discusses the Board’s implementation of the prescription drug formulary, which will start impacting claims by year-end.

The April 2017 reform legislation amended WCL § 13-p to mandate that the chair of the Workers’ Compensation Board adopt a comprehensive prescription drug formulary, which the legislature directed “include a tiered list of high-quality, cost-effective medications that are pre-approved to be prescribed and dispensed, as well as additional non-preferred drugs that can be prescribed with prior approval.” Although delayed, the chair adopted a Drug Formulary on June 5, 2019, which applies in all claims, including controverted claims, regardless of the date of accident or disablement, and regardless of where the claimant lives. The formulary will be updated at least annually to account for changes to medications available on the market.

The formulary will apply to new prescriptions effective December 5, 2019, and to refill and renewal prescriptions effective June 5, 2020. A “new” prescription is a prescription for a drug that the claimant is not currently taking (different drug or different strength or frequency). A “renewal” is a newly-written prescription for continuation/renewal of a drug (same drug, strength, and frequency) that the claimant has been taking, but for which there are no available refills. A “refill” is any subsequent fill of a prescription when the number of refills is explicitly included in the original prescription. As of December 5, 2019, any new prescription must be for a formulary drug, and a provider must obtain prior authorization for any non-formulary drug prior to writing a new prescription. Prior to June 5, 2020, providers and claimants must plan for a transition to a formulary drug. If such a transition is considered not medically appropriate, the provider must obtain prior authorization for a refill or renewal of a non-formulary drug well in advance of June 5, 2020. On or after June 5, 2020, all refills or renewals of prescriptions must use a formulary drug unless prior authorization has been obtained before the date of the refill or renewal.

With regard to refills and renewals, carrier, self-insured employers (SIEs), and third-party administrators (TPAs) are required to notify claimants and providers by December 5, 2019 if a currently prescribed drug is not included on the formulary. The chair has specified the required format for such notifications: Injured Worker Formulary Notification and Provider Formulary Notification.

Formulary Drugs

Formulary drugs do not require prior authorization, and are designated as either “Phase A,” “Phase B,” or “Perioperative.” Phase A drugs may be prescribed/dispensed within the first 30 days following an accident/injury or until the carrier accepts or the board establishes the claim, whichever occurs sooner, for up to a 30-day supply. Phase B drugs may be prescribed/dispensed after 30 days following an accident/injury or when the carrier has accepted or the Board has established the claim, whichever occurs sooner, for up to a 90-day supply. However, when a body part/illness has been accepted (with or without liability) or established, Phase B drugs must be prescribed in accordance with, as applicable, the adopted Medical Treatment Guidelines (MTG). Phase B drugs designated as “2nd” line therapy may only be prescribed/dispensed following an unsuccessful trial of a first-line drug prescribed in accordance with Phase B and, as applicable, the adopted MTG. Perioperative drugs may be prescribed/dispensed during the perioperative period (4 days before through 4 days after the claimant goes into the hospital, clinic, or doctor’s office for surgery, with the day of surgery being day 0). Accordingly, carriers and SIEs should advise their pharmacy networks, including pharmacy benefit managers, when surgery has been authorized or scheduled.

Some formulary drugs – namely, certain controlled substances, muscle relaxants, and anti-infectives, including antibiotics and post-exposure medications – are further marked with a “Special Consideration” indication (1, 2, or 3), which, when applicable, limit the drug’s prescription and dispensing (1) to one time only without a prior authorization, for a maximum of a 7-day supply, during the phase of the formulary under which it is contained; (2) during the applicable phase of the formulary, for the quantity indicated by the prescriber; and/or (3) to the short acting formulation of the product.

In the event that a conflict exists between the Board’s MTGs and the formulary, the provisions of the MTGs shall prevail, unless the drug was prescribed in accordance with Phase A or Phase B of the formulary.

Non-Formulary Drugs

Prior authorization is required for: (1) prescription/dispensing of a drug other than as described in the formulary; (2) drugs not listed on the formulary; (3) a formulary brand name drug, when a generic is available; (4) combination products, unless specifically listed in the formulary; (5) a brand name drug when a generic version with the same active ingredient(s) is commercially available in a different strength/ dosage; and (6) compound drugs. The requirement of prior authorization for prescription/dispensing of compound drugs was specifically directed by the April 2017 reform legislation. If prior authorization is not obtained prior to the dispensing of a drug when required, payment for the drug may be denied. When responsibility for payment is apportioned between more than one carrier or SIE, the provider must seek prior authorization from each carrier and SIE.

Prior Authorization Process

First Level Review: The provider shall submit a request for prior authorization, in the manner prescribed by the chair, to the carrier, SIE, or, when designated, the pharmacy benefits manager (PBM). The request may include the quantity to be prescribed and number of refills or duration of the prescription. If the duration is not stated, the default is 30 days; the prior authorization request may not exceed 365 days. The carrier, SIE, or PBM must approve, partially approve, or deny the prior authorization request within 4 calendar days. Failure to timely respond within 4 calendar days may result in the request being deemed approved as prescribed via Order of the chair. A “partial approval” authorizes the requested drug, but limits the length of time, quantity prescribed, or number of refills from that requested by prescriber. A partial approval or denial must provide a specific reason for such response with reference to the specific request made by the prescriber, and provide information regarding how to request review of the denial/partial approval from the carrier or SIE’s physician, which is defined as a physician or physicians, licensed by New York State or the state where he/she practices, who is: (1) employed or contracted by the carrier or SIE; or (2) is employed by a URAC-accredited company retained by the carrier or SIE through a contract to review claims requests for non-formulary agents and advise the carrier or SIE; and (3) is not employed or contracted by the carrier or SIE’s pharmacy benefits network.

Second Level Review: Within 10 calendar days of a denial or partial approval, the prescriber may request review by the carrier/SIE’s physician. Such request for review must include: (1) all information submitted by the prescriber for the First Level Review; (2) the response from the carrier, SIE, or PBM; (3) all information provided to the prescriber related to the First Level Review denial or partial approval; and (4) additional information from the prescriber further justifying the need for the requested non-formulary drug, responding to the reason(s) stated in the First Level Denial. The carrier/SIE’s physician must approve, partially approve, or deny the prior authorization request within 4 calendar days. Failure to timely respond may result in the request being deemed approved as prescribed via Order of the chair.

Third Level Review: Within 10 calendar days of a denial or partial approval by the carrier/SIE’s physician of a Second Level Review, the prescriber may request review by the Board’s Medical Director’s Office. Such request for review must include: (1) all documentation submitted in support of the First and Second Level Reviews; (2) all information associated with the denial or partial approval issued from the First and Second Level Reviews; (3) the prescriber’s response to the reason(s) stated in the Second Level Denial; and (4) additional information from the prescriber further justifying the need for the requested non-formulary drug, responding to the reason(s) stated in the Second Level Denial. The decision by the Medical Director’s Office is final and binding on all parties. If a Third Level Review is denied, the prescriber may not submit a request for prior authorization for the same medication unless he/she submits evidence that there has been a change in claimant’s medical condition that renders the denial of the request for prior authorization no longer applicable to the claimant’s current medical condition.

Carriers, SIEs, and TPAs were required to provide the Board, in the manner prescribed by the chair, with the name and contact information for the point(s) of contact for the First and Second Level Review by July 4, 2019, but no later than December 5, 2019, and are required to keep such information up-to-date thereafter. Failure to provide the Board with such name and contact information by December 5, 2019, or to keep such information up-to-date thereafter, may subject the carrier/SIE/TPA to Orders of the chair approving Prior Authorization requests and penalties pursuant to WCL § 114-a(3) for every case where Prior Authorization was requested. However, the chair has yet to specify the manner in which such name and contact information is to be provided, or the manner in which requests for prior authorization shall be submitted by providers. It is expected that the Board will make further announcements regarding the prior authorization process by December 5, 2019.

Chartwell Commentary

The formulary is expected to reduce medical exposure, particularly in older claims where claimants are currently prescribed narcotics/opioids, due to its restrictions on the prescription and dispensing of narcotics/opioids. The State, and in turn the Board, have demonstrated a keen interest in reducing ongoing opioid use in recent years. In the New York State Department of Health’s 2018 Opioid Annual Data Report, it was noted that opioid overdose deaths among New York State residents nearly tripled from 2010 to 2016 (from 5.4 deaths per 100,000 population in 2010 to 15.1 deaths per 100,000 in 2016). Public Health Law § 3309(5) requires that the State publish this report on statewide opioid overdose data annually to “assist agencies and programs across the state in planning and tailoring interventions to address the ongoing opioid crisis.”

Reflecting the Board’s effort to combat the increased reliance on opioid medications by workers’ compensations claimants, the drug formulary does not allow for prescription of narcotics after the first 30 days following an injury, except in the immediate pre- and post-operative periods, unless prior authorization is obtained. Furthermore, on or after December 5, 2019, during the 30 days following an injury, narcotics may not exceed a single 7-day supply. As for claimants who are already on long-term opioids, they and their providers must plan for a transition to a drug formulary medication prior to June 5, 2020. If a provider considers such a transition not medically appropriate, the provider must obtain prior authorization for a refill or renewal of a non-formulary narcotic well in advance of June 5, 2020.

Despite the anticipated benefits, the 4-calendar-day response time for prior authorization requests is unreasonably short – particularly where a request is received late on a Friday before a long weekend – and places another heavy administrative burden on payors. Therefore, the actual benefit remains to be seen, since failure to timely respond will result in the request being deemed approved as prescribed, and procedures need to be put into place as soon as possible to ensure timely responses.

In sum, to take advantage of the formulary’s restrictions on prescription medications, it is important that payors: (1) notify claimants and providers by December 5, 2019 if a currently prescribed drug is not included on the formulary, (2) provide the Board with the name and contact information for the point(s) of contact for First and Second Level Reviews no later than December 5, 2019; and (3) timely and properly respond to all provider requests for prior authorization.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Chartwell Law | Attorney Advertising

Written by:

Chartwell Law
Contact
more
less

Chartwell Law on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.